Guanfacine for the treatment of attention deficit hyperactivity disorder in children and adolescents.
Expert Rev Neurother
; 15(4): 347-54, 2015 Apr.
Article
em En
| MEDLINE
| ID: mdl-25800130
ABSTRACT
Guanfacine is an α2A-adrenoreceptor agonist currently indicated for the treatment of attention deficit hyperactivity disorder (ADHD). This article reviews the chemistry, pharmacodynamics and pharmacokinetics of guanfacine, as well as the clinical trial literature on guanfacine for the treatment of ADHD in children and adolescents, mainly focusing on the use of guanfacine extended-release (GXR). Six already published prospective randomized controlled trials (RCTs) and one unpublished RCT study were identified for GXR in the treatment of ADHD. All RCTs trials showed superiority over placebo on the primary outcome measure. Guanfacine, especially XR, seems to be an effective and safe treatment option for ADHD in children and adolescents.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Transtorno do Deficit de Atenção com Hiperatividade
/
Guanfacina
/
Agonistas de Receptores Adrenérgicos alfa 2
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Child
/
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article